(4R)-3-(Mercaptoacyl)-4-thiazolidinecarboxylic acids (III) were synthesized and their inhibitory activities against angiotensin-converting enzyme (ACE) were examined in vitro and in vivo. (4R)-3-[(2S)-3-Mercapto-2-methylpropanoyl]-4-thiazolidinecarboxylic acid (4a) was the most potent orally active inhibitor of ACE among the derivatives and its activity was almost same as that of (2S)-1-[(2S)-3-mercapto-2-methylpropanoyl] proline (8).
合成了(4R)-3-(巯基)-4-
噻唑烷
羧酸(III),并在体外和体内检测了它们对
血管紧张素转换酶(ACE)的抑制活性。 (4R)-3-[(2S)-3-巯基-2-甲基丙酰]-4-
噻唑烷
甲酸(4a)是衍
生物中最有效的口服活性ACE
抑制剂,其活性与(2S)几乎相同)-1-[(2S)-3-巯基-2-甲基丙酰基]脯
氨酸(8)。